In specific populations with known mutations in the breast cancer (BRCA 1 and BRCA 2) genes, as well as in those with a homologous recombination deficiency, the use of PARP (poly-ADP ribose polymerase) inhibitors in combination with anti-VEGF (vascular endothelial growth factor) therapy has achieved a significant prolongation of recurrence-free and overall survival [7]. The gene discussed is VEGFA; the disease is breast carcinoma.